Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.
The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.
C4 Therapeutics director Donna Roy Grogan received a new stock option grant. She was awarded options covering 62,000 shares of Common Stock at an exercise price of $4.25 per share. These options are a compensation-related award, not an open-market stock purchase or sale.
The option will vest and become fully exercisable on the earlier of June 24, 2027 or the company’s next annual meeting of stockholders, provided she continues serving on the Board through that date. Following this grant, her reported holdings in this option award total 62,000 derivative securities.
C4 Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting.
Stockholders gave a non-binding, advisory approval of named executive officer compensation and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the shares counted for the evergreen increase calculation.
C4 Therapeutics filed a report highlighting new clinical data and investor materials for its IKZF1/3 degrader cemsidomide in relapsed/refractory multiple myeloma. A fully enrolled Phase 1 trial of cemsidomide plus dexamethasone in 73 heavily pretreated patients showed a 53% overall response rate at the 100 µg once-daily recommended Phase 2 dose and 36% across all doses, with some responses deepening over time and minimal residual disease negativity in select patients. Median progression-free survival was 3.9 months and median duration of response was 7.9 months. Safety was characterized mainly by on‑target neutropenia, with 58% experiencing grade 3/4 neutropenia, few dose reductions and no discontinuations attributed to cemsidomide. The company is now enrolling a Phase 2 single‑arm study in fourth‑line and later multiple myeloma and a Phase 1b combination trial with the bispecific antibody elranatamab, while also outlining a broader strategy in oncology and inflammation/neuroinflammation indications.
C4 Therapeutics director Kenneth Carl Anderson exercised stock options to acquire 1,070 shares of common stock on June 1, 2026. The options were exercised at a price of $2.11 per share for cash, and no shares were sold in connection with the exercise.
Following the exercise, Anderson directly holds 69,300 shares of C4 Therapeutics common stock. Additional shares are held indirectly through several revocable and irrevocable trusts associated with Anderson and Cynthia E. Anderson, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
CCCC reported a same-day exercise-and-sale of stock options granted under its 2020 Equity Incentive Plan. The filing states 29,080 options were granted on 02/14/2025; of those, 9,087 vested and were exercised and sold pursuant to a same-day sale transaction. The filing lists brokerage details for the transaction.
C4 Therapeutics, Inc. Schedule 13G: Squadron Master Fund LP and affiliated filers report beneficial ownership of 5,550,000 shares of common stock, representing 5.0% of the class based on 110,567,222 shares outstanding as of May 1, 2026.
The filing states the holdings reflect shared voting and dispositive power and includes a Rule 13d-4 disclaimer that the adviser and named partners disclaim beneficial ownership.
C4 Therapeutics, Inc. ownership disclosure: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen report shared beneficial ownership of 169,096 shares of Common Stock, representing 0.2% of the class, as of the close of business on March 31, 2026.
The filing states these reporting persons own no shares directly and that shared voting and dispositive power over the reported shares is held through investment funds and management arrangements. The statement disclaims that this filing should not be construed as admission of beneficial ownership for purposes of Section 13.
C4 Therapeutics reported a change in its senior finance leadership roles. The company determined that Mark Mossler will no longer serve as Chief Accounting Officer, effective May 15, 2026, and stated that his departure does not involve any disagreement about financial reporting, operations, policies or practices.
Kendra R. Adams, currently Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the company’s principal accounting officer, also effective May 15, 2026. She will not receive additional compensation for this role, and no existing plans or arrangements involving her have been changed.
C4 Therapeutics reports that Sirenia Capital Management and Alex Silverstein collectively beneficially own 23,505,000 shares of Common Stock, representing 9.9% of the class after applying a 9.99% ownership blocker.
The filing states the percentage is calculated using 97,578,175 shares outstanding as of February 23, 2026 and notes that the reported holdings include 14,170,000 shares issuable upon exercise of warrants subject to the 9.99% Blocker; as a result, the Reporting Persons cannot currently exercise all warrants because of that limitation.